Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 6/20 | 0.41 |
| ▸ | HTT | P42858 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1627210 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNATSHRHTTMAPK1 | |
| SCHEMBL12410744 | 0.80 | TSHR (0.41) | SMN1; SMN2LMNATSHRHTTMAPK1 | |
| SCHEMBL8545976 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNATSHRHTTMAPK1 | |
| SCHEMBL8550018 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNATSHRHTTMAPK1 | |
| SCHEMBL17738012 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNATSHRHTTMAPK1 | |
| SCHEMBL9237010 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNATSHRHTTMAPK1 | |
| SCHEMBL9235153 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNATSHRHTTMAPK1 | |
| SCHEMBL9726468 | 0.77 | TSHR (0.41) | SMN1; SMN2LMNATSHRHTTMAPK1 | |
| SCHEMBL21720342 | 0.75 | SMN1; SMN2 (0.35) | SMN1; SMN2LMNATSHRHTTMAPK1 | |
| SCHEMBL3848503 | 0.75 | TSHR (0.41) | SMN1; SMN2LMNATSHRHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113754589-B | Compositions, methods, and systems for synthesizing and using contrast agents | 蓝瑟斯医学影像公司 | 2024-09-27 | — | — | CN | disclosed |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-113754589-A | Compositions, methods, and systems for synthesis and use of contrast agents | 蓝瑟斯医学影像公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-107311935-B | Compositions, methods, and systems for synthesis and use of contrast agents | 蓝瑟斯医学影像公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-4874861-A | Pyridazinone derivatives, preparation thereof, and insecticidal, acaricidal, nematicidal, fungicidal compositions | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1989-10-17 | — | — | US | disclosed |
| EP-0186817-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-08-02 | — | — | EP | disclosed |
| US-4837217-A | Pyridazinone derivatives, preparation thereof, and insecticidal, acaricidal, nematicidal, fungicidal compositions | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1989-06-06 | — | — | US | disclosed |
| US-4783462-A | 3(2H)pyridazinone, and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1988-11-08 | — | — | US | disclosed |
| CN-86102700-A | The preparation method of pyridazinone derivative and desinsection thereof, kill mite, nematicide, fungicide composition | — | 1986-12-17 | — | — | CN | disclosed |
| EP-0199281-A2 | Pyridazinone derivatives, preparation thereof, and insecticidal, acaricidal, nematicidal, fungicidal compositions | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-10-29 | — | — | EP | disclosed |
| CN-85108650-A | The preparation method of pyridazinone derivative, and insecticidal constituent kill acaricidal composition, and the nematicide composition kills (very) bacterium composition | — | 1986-09-24 | — | — | CN | disclosed |
| EP-0193853-A2 | 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-09-10 | — | — | EP | disclosed |
| EP-0186817-A1 | 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-07-09 | — | — | EP | disclosed |
| EP-0183212-A2 | Pyridazinone derivatives, preparation thereof, and insecticidal, acaricidal, nematicidal, fungicidal compositions | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | SMN1; SMN2 2969/4885LMNA 3348/4885TSHR 2215/4885 |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | FABP3, TNNI3, TNNT2 | SMN1; SMN2 699/4885LMNA 1449/4885TSHR 3187/4885 |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | SMN1; SMN2 2969/4885LMNA 3348/4885TSHR 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.